ReviewEuropean respiratory review : an official journal of the European Respiratory Society2017
The changing landscape of chronic thromboembolic pulmonary hypertension management.
Review in European respiratory review : an official journal of the European Respiratory Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 78 citations in OpenAlex.
- Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.The European respiratory journal · 2022Trial
- Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.The European respiratory journal · 2019Trial
- Rescue Balloon Pulmonary Angioplasty Prior to Pulmonary Endarterectomy With Concomitant Mitral Valve Plasty in High-Risk Operable CTEPH.Pulmonary circulation · 2026Article
- Preoperative of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension using virtual balloon expansion: a pilot study.Frontiers in bioengineering and biotechnology · 2026Article
- Why Is Pulmonary Endarterectomy Underused in Japan? Epidemiology, Genetics, and a Practical Operability Framework.Pulmonary circulation · 2025Review
- Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension.Pulmonary therapy · 2025Article
- The role of vasculature and angiogenesis in respiratory diseases.Angiogenesis · 2024Review
- Riociguat as bridging therapy to pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Change in Right-to-Left Shunt Fraction in Patients with Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Endarterectomy.Journal of cardiovascular development and disease · 2023Article
- Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019-2020.Medicina (Kaunas, Lithuania) · 2023Article
- Pulmonary artery blood flow dynamics in chronic thromboembolic pulmonary hypertension.Scientific reports · 2023Article
- Impact of residual pulmonary hypertension on long-term outcomes after pulmonary endarterectomy in the modern era.Pulmonary circulation · 2023Article
- Balloon pulmonary angioplasty followed by pulmonary endarterectomy: Combination treatment for high-surgical-risk patients with chronic thromboembolic pulmonary hypertension.Interdisciplinary cardiovascular and thoracic surgery · 2023Article
- Predictors of Improvement in Exercise Tolerance After Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.Journal of the American Heart Association · 2023Article
- Quantification of pulmonary perfusion using LSIM-CT correlates with pulmonary hemodynamics in patients with CTEPD.Frontiers in cardiovascular medicine · 2023Article
- Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.Journal of pharmacy practice · 2022Review
- Recognizing pulmonary hypertension following pulmonary thromboendarterectomy: A practical guide for clinicians.Pulmonary circulation · 2022Review
- Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team.Annals of cardiothoracic surgery · 2022Review
- Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Article
- A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension.American journal of physiology. Heart and circulatory physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients with chronic thromboembolic pulmonary hypertension (CTEPH), the current standard of care involves surgical removal of fibro-thrombotic obstructions by pulmonary endarterectomy. While this approach has excellent outcomes, significant proportions of patients are not eligible for surgery or suffer from persistent/recurrent pulmonary hypertension after the procedure. The availability of balloon pulmonary angioplasty and the approval of the first medical therapy for use in CTEPH have significantly improved the outlook for patients ineligible for pulmonary endarterectomy. In this comprehensive review, we discuss the latest developments in the rapidly evolving field of CTEPH. These include improvements in imaging modalities and advances in surgical and interventional techniques, which have broadened the range of patients who may benefit from such procedures. The efficacy and safety of targeted medical therapies in CTEPH patients are also discussed, particularly the encouraging data from the recent MERIT-1 trial, which demonstrated the beneficial impact of using macitentan to treat patients with inoperable CTEPH, including those on background therapy. As the treatment options for CTEPH improve, hybrid management involving more than one intervention in the same patient may become a viable option in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.